Pyxis Oncology, Inc. PYXS 深 沪
已收盘 12-19 16:00:00 美东时间
1.275
-0.455
-26.30%
华盛通- 最 高1.80
- 今 开1.75
- 成交量 539.40万股
- 最 低 1.23
- 昨 收 1.73
- 总市值 7938.69万
- 52周最高 5.55
- 市盈率 静 --
- 换手率 8.66%
- 52周最低 0.8332
- 委 比 64.02%
- 总股本 6226.42万
- 历史最高 19.00
- 量 比 2.11
- 振 幅 32.95%
- 历史最低 0.8332
- 每 手 1
- 风险率 1.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Analysts Sound Alarm On Pyxis Oncology's Tiny Trial
Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.
12-19 22:07
Pyxis Oncology shares are trading lower. The company announced preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin.
Pyxis Oncology shares are trading lower. The company announced preliminary data...
12-18 22:16
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Athira Pharma (NASDAQ:ATHA) stock increased by 30.6% to $5.4 during Th...
12-18 20:05
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Stephens & Co. Maintains Overweight on Pyxis Oncology, Raises Price Target to $8
Stephens & Co. analyst Sudan Loganathan maintains Pyxis Oncology (NASDAQ:PYXS) with a Overweight and raises the price target from $5 to $8.
11-24 22:04
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Guggenheim Maintains Buy on Pyxis Oncology, Raises Price Target to $7
Guggenheim analyst Brad Canino maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the price target from $5 to $7.
11-04 23:37
Pyxis Oncology shares are trading higher. The company reported Q3 financial results.
Pyxis Oncology shares are trading higher. The company reported Q3 financial res...
11-04 00:50
Pyxis Oncology Q3 EPS $(0.35) Misses $(0.34) Estimate
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.34) by 2.04 percent. This is unchanged from the same period last year.
11-03 20:09
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
Pyxis Oncology announced that it will present translational data for micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate (ADC) targeting the extracellular matrix, at ESMO 2025 and AACR-NCI-EORTC 2025. MICVO employs a unique three-pronged mechanism of action, including direct tumor cell killing, bystander effect, and immunogenic cell death, to combat solid tumors. Data highlight MICVO's effects on tumor microenvironment remod...
10-13 20:05
